2021 Revenues ($USD) : $4,386,300,000
2021 R&D spend : $760,700,000
2021 Number of Employees : 15,878
Fiscal Year End : 12/31/2020
Key People : Michael Mussallem, chair and CEO; Donald Bobo, CVP, strategy and corporate development; Todd Brinton, CVP, advanced technology, chief scientific officer; Daveen Chopra, CVP, surgical structural heart; Dirksen Lehman, CVP, public affairs; Jean-Luc Lemercier, CVP, EMEA, Canada and Latin America; Christine McCauley, CVP, human resources; Gary Sorsher, VP, quality and regulatory compliance; Joseph Nuzzolese, CVP, global supply chain and quality; Katie Syzman, CVP, critical care; Scott Ullem, CVP, CFO; Huimin Wang, CVP, Japan, Asia and Pacific; Arnold Pinkston, CVP, general counsel; Larry Wood, CVP, transcatheter aortic valve replacement; Bernard Zovighian, CVP, transcatheter mitral and tricuspid therapies.

About the company: Edwards Lifesciences is one of medtech's biggest heart valve makers. The Irvine, California-based company treats advanced cardiovascular disease with its numerous heart valve therapies and critical care and vascular technologies. One of Edwards' most known specialties is its transcatheter aortic valve replacement (TAVR) devices. The medtech giant also specializes in blood conservation, enhanced surgical recovery, clot management, hypotension management, infection control and sepsis shock management. –DK